AMNEAL PHARMACEUTICALS, INC. (AMRX) Operating income 2016–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) annual operating income history from SEC filings — each fiscal year as reported.
$394.1MFY2025 · since FY2016: $284.9M → $394.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $394.1M | +58.1% |
| FY2024 | $249.3M | +22.0% |
| FY2023 | $204.4M | +315.3% |
| FY2022 | -$94.9M | -162.2% |
| FY2021 | $152.7M | +67.5% |
| FY2020 | $91.2M | +136.7% |
| FY2019 | -$248.7M | -1164.1% |
| FY2018 | -$19.7M | -108.0% |
| FY2017 | $245.1M | -14.0% |
| FY2016 | $284.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Gross marginAMRX Operating marginAMRX Operating cash flowAMRX Free cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →